.
.
.
.
Coronavirus

Europe could have herd immunity against COVID-19 by July: EU commissioner

Published: Updated:

Europe could have herd immunity against COVID-19 by July, a European Union commissioner has said, as incoming jabs are expected to speed up the continent’s sluggish vaccine rollout.

The note of optimism comes even as several European countries have started reimposing restrictions as they contend with surging coronavirus infections, and after mixed messaging on the safety of a key jab.

For more coronavirus news, visit our dedicated page.

“Let’s take a symbolic date: by July 14, we have the possibility of achieving immunity across the continent,” Thierry Breton, the EU’s commissioner for the internal market told French broadcaster TF1.

“We’re in the home stretch, because we know that to beat this pandemic there’s just one solution: vaccination. The vaccines are arriving,” he said.

More than a third of France’s population is now under renewed lockdown, while frustrations over virus curbs spilled into weekend demonstrations in Germany, Amsterdam, Bulgaria and Switzerland.

Europe’s battle to prevent a deadly third wave of infections has been complicated by a patchy vaccine drive that included several nations temporarily halting AstraZeneca’s shots in response to isolated cases of blood clots.

Most have since resumed using the vaccine after the European Medicines Agency found it “safe and effective."

But AstraZeneca has delivered only 30 percent of the 90 million doses it promised the EU for the first quarter.

For all the latest headlines follow our Google News channel online or via the app.

Breton said he was confident more vaccines will arrive soon, with 300-350 million doses expected between March and June.

He added that 55 factories would now be producing vaccines in Europe.

Read more:

UAE may ‘soon’ be first country to vaccinate all population, reach herd immunity: Doc

Nearly a dozen countries resume AstraZeneca COVID-19 vaccines

Despite vaccine delays, EU insists on target for vaccinating 70 pct of adults by end